^
Association details:
| Biomarker: | Low PLR |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1008P - The safety and efficacy of PD-1 inhibitor (Sintilimab) combined with conventional transarterial chemoembolization (cTACE) for the initial treatment of the stage BCLC B hepatocellular carcinoma (HCC) beyond up-to-seven criteria
Published date:
10/16/2023
Excerpt:
This is a single-arm, phase II study(NCT04842565). Eligible HCC pts were treated cTACE and sintilimab (200mg, IV, Q3W)….Low PLR were associated with more tumor shrinkage.
Trial ID: